Agricultural products, such as pesticides, plant growth regulators, fungicides, herbicides, and insecticides, may be formulated to include one or more surfactants, from one or more surfactant classes, such as derivatives of amino acids that have surface-active properties.

A novel cationic lipid having a structure as represented by general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pharmaceutical composition containing said cationic lipid, preparation and application thereof. A cationic liposome containing the cationic lipid represented by formula (1), can improve the loading rate and transport rate of drugs, particularly nucleic acid drugs. The terminus of the novel cationic lipid can contain a fluorescent group or a targeting group, so that the cationic liposome pharmaceutical composition containing the cationic lipid can have fluorescent or targeting function. A formulation of cationic liposome pharmaceutical composition containing nucleic acid exhibiting a very good gene complexing ability and high gene transfection ability, thereby further improves the gene therapeutic and/or gene diagnostic effect of the drug, and provides more selectable cationic lipids in the field of drug delivery.

A novel cationic lipid having a structure as represented by general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pharmaceutical composition containing said cationic lipid, preparation and application thereof. A cationic liposome containing the cationic lipid represented by formula (1), can improve the loading rate and transport rate of drugs, particularly nucleic acid drugs. The terminus of the novel cationic lipid can contain a fluorescent group or a targeting group, so that the cationic liposome pharmaceutical composition containing the cationic lipid can have fluorescent or targeting function. A formulation of cationic liposome pharmaceutical composition containing nucleic acid exhibiting a very good gene complexing ability and high gene transfection ability, thereby further improves the gene therapeutic and/or gene diagnostic effect of the drug, and provides more selectable cationic lipids in the field of drug delivery.

Disclosed is a novel amino acid derived surfactant which is prepared by forming the salt of an alkylaminopropionic acid and a basic amino acid such as arginine which is useful in cosmetic and personal care compositions.

The invention provides a compound of formula (I): [insert formula (I)] wherein X, Y, and R.sup.1-R.sup.4 have any of the values defined in the specification, and salts thereof, as well as compositions comprising the compounds or salts. The compounds are useful for treating diseases associated with impaired mitochondrial function in an animal. ##STR00001##

The invention provides a compound of formula (I): [insert formula (I)] wherein X, Y, and R.sup.1-R.sup.4 have any of the values defined in the specification, and salts thereof, as well as compositions comprising the compounds or salts. The compounds are useful for treating diseases associated with impaired mitochondrial function in an animal. ##STR00001##

The absorption of CO.sub.2 from a gas mixture by contacting the gas mixture with an absorption medium that comprises water and 5 to 50 wt % of amino acid salts of formula R.sup.1R.sup.2CHNHCH.sub.2COOK, in which R.sup.1 and R.sup.2 are n-alkyl radicals and the radicals R.sup.1 and R.sup.2 together have 2 to 4 carbon atoms, affords a high CO.sub.2 absorption capacity per unit weight in the cyclical operation of absorption and desorption.

Provided herein are lipids having the Formula I or Formula Ia: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, X.sup.1, X.sup.2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (nirogacestat).

The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (nirogacestat).